Patent Grant
10010656
1. Field of the Invention
The present invention relates generally to tissue treatment systems and in particular to dressings for distributing reduced pressure to and collecting and storing fluid from a tissue site.
2. Description of Related Art
Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifold device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad may be incorporated into a dressing having other components that facilitate treatment.
The problems presented by existing collection canisters are solved by the systems and methods of the illustrative embodiments described herein. In one illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site, and a liquid-air separator is positioned between the absorbent layer and the pump to inhibit liquid from entering the pump.
In another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver a reduced pressure to the tissue site. A diverter layer is positioned between the absorbent layer and the pump, and the diverter layer includes a plurality of apertures to transmit the reduced pressure from the pump to the absorbent layer. A cover is positioned over the pump, the diverter layer, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the diverter layer and the pump to inhibit liquid from entering the pump.
In another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site and an absorbent layer in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A diverter layer is adjacent the absorbent layer, and the diverter layer is formed from a substantially gas-impermeable material. The diverter layer includes a plurality of apertures in fluid communication with the absorbent layer to increase an amount of time that the absorbent layer is able to distribute reduced pressure. A pump is in fluid communication with the plurality of apertures of the diverter layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the diverter layer, the absorbent layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the diverter layer and the pump to inhibit liquid from entering the pump.
In still another illustrative embodiment, a reduced pressure dressing for applying reduced pressure treatment to a tissue site is provided. The reduced pressure dressing includes an interface layer adapted to be positioned at the tissue site. A first manifold layer is in fluid communication with the interface layer, and an absorbent layer is in fluid communication with the first manifold layer to absorb liquid from at least one of the first manifold layer, the interface layer, and the tissue site. A diverter layer is formed from a substantially gas-impermeable material, and the diverter layer includes a plurality of spaced apertures in fluid communication with the absorbent layer. A second manifold layer is in fluid communication with the diverter layer. A pump is in fluid communication with the second manifold layer to deliver a reduced pressure to the tissue site. A cover is positioned over the pump, the second manifold layer, the diverter layer, the absorbent layer, the first manifold layer, and the interface layer to maintain the reduced pressure at the tissue site. A liquid-air separator is positioned between the second manifold and the pump to inhibit liquid from entering the pump.
In yet another illustrative embodiment, a method for collecting liquid in a dressing positioned at a tissue site includes generating a reduced pressure using a pump positioned within the dressing. A liquid is absorbed from the tissue site and is stored in the dressing. The liquid is prevented from entering the pump.
In another illustrative embodiment, a reduced pressure dressing adapted to distribute a reduced pressure to a tissue site includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver the reduced pressure to the tissue site, a diverter layer is positioned between the absorbent layer and the pump. The diverter layer is formed from a substantially gas-impermeable material and includes a surface area smaller than a surface area of the absorbent layer such that flow is directed around at least one perimeter edge of the diverter layer. A cover is positioned over the diverter layer to maintain the reduced pressure at the tissue site.
In still another illustrative embodiment, a reduced pressure dressing adapted to distribute a reduced pressure to a tissue site is provided. The dressing includes an interface layer adapted to be positioned at the tissue site. An absorbent layer is in fluid communication with the interface layer to absorb liquid from at least one of the interface layer and the tissue site. A pump is in fluid communication with the absorbent layer to deliver the reduced pressure to the tissue site, and a diverter layer is positioned between the absorbent layer and the pump. The diverter layer is formed from a substantially gas-permeable, liquid impermeable material. A cover is positioned over the diverter layer to maintain the reduced pressure at the tissue site.
Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of several illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
The term “reduced pressure” as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure reduction applied to the tissue site may be significantly less than the pressure reduction normally associated with a complete vacuum. Reduced pressure may initially generate fluid flow in the area of the tissue site. As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.
The term “tissue site” as used herein refers to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term “tissue site” may further refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure tissue treatment may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
Reduced pressure treatment systems are often applied to large, highly exudating wounds present on patients undergoing acute or chronic care, as well as other severe wounds that are not readily susceptible to healing without application of reduced pressure. Low-severity wounds that are smaller in volume and produce less exudate have generally been treated using advanced dressings instead of reduced pressure treatment. These advanced dressings, however, are not adapted for use with reduced pressure and are subject to several drawbacks when used in conjunction with reduced pressure. For example, these current dressings may fail to make optimal use of fluid storage capacity in the dressing. Additionally, existing dressings are not configured to adequately transmit reduced pressure, especially as the dressings begin to absorb and store fluid.
Currently, the use of reduced pressure treatment is not considered a viable or affordable option for low-severity wounds due to the manpower required to monitor and change system components, the requirement for trained medical personnel overseeing treatment, and the cost of treatment. For example, the complexity of current reduced pressure treatment systems limits the ability of a person with little or no specialized knowledge from administering such treatment to oneself or others. The size of current reduced pressure treatment systems also impairs the mobility of both the treatment system and the person to whom the treatment is being applied. For example, current reduced pressure treatment systems require the use of a separate canister that stores exudate or other liquid from the tissue site. Current reduced pressure treatment systems are also typically non-disposable after each treatment, and require electrical components or other powered devices in order to apply the reduced pressure used in treatment.
Reduced Pressure Dressing
Referring to
The reduced pressure source 110 may be housed within a reduced pressure treatment unit, which may also contain sensors, processing units, alarm indicators, memory, databases, software, display units, and user interfaces that further facilitate the application of reduced pressure treatment to the tissue site 108. In one example, a sensor or switch (not shown) may be disposed at or near the reduced pressure source 110 to determine a source pressure generated by the reduced pressure source 110. The sensor may communicate with a processing unit that monitors and controls the reduced pressure that is delivered by the reduced pressure source 110. Delivery of reduced pressure to the reduced pressure dressing 104 and tissue site 108 encourages new tissue growth by maintaining drainage of exudate from the tissue site, increasing blood flow to tissues surrounding the tissue site, and creating microstrain at the tissue site.
Referring to
The interface layer 220 of the reduced pressure dressing 104 is adapted to contact the tissue site 108. The interface layer 220 may be partially or fully in contact with the tissue site 108 being treated by the reduced pressure dressing 104. When the tissue site 108 is a wound, the interface layer 220 may partially or fully fill the wound.
The interface layer 220 may be any size, shape, or thickness depending on a variety of factors, such as the type of treatment being implemented or the nature and size of the tissue site 108. For example, the size and shape of the interface layer 220 may be customized by a user to cover a particular portion of the tissue site 108, or to fill or partially fill the tissue site 108. Although the interface layer 220 illustrated in
In one illustrative embodiment, the interface layer 220 is a foam material that functions as a manifold to provide reduced pressure to the tissue site 108 when the interface layer 220 is in contact with or near the tissue site 108. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, the interface layer 220 is an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.
In the example in which the interface layer 220 is made from a hydrophilic material, the interface layer 220 also functions to wick fluid away from the tissue site 108, while continuing to provide reduced pressure to the tissue site 108 as a manifold. The wicking properties of the interface layer 220 draw fluid away from the tissue site 108 by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
The interface layer 220 may further promote granulation at the tissue site 108 when a reduced pressure is applied through the reduced pressure dressing 104. For example, any or all of the surfaces of the interface layer 220 may have an uneven, coarse, or jagged profile that causes microstrains and stresses at the tissue site 108 when reduced pressure is applied through the interface layer 220. These microstrains and stresses have been shown to increase new tissue growth.
In one embodiment, the interface layer 220 may be constructed from bioresorbable materials that do not have to be removed from a patient's body following use of the reduced pressure dressing 104. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The interface layer 220 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the interface layer 220 to promote cell-growth. A scaffold is a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
The seal layer 222 of the reduced pressure dressing 104 includes an aperture or opening 231 and provides a seal around the tissue site 108. The seal layer 222 may serve as a gasket around a portion of the tissue site 108 to prevent reduced pressure applied to the reduced pressure dressing 104 from leaking out of the reduced pressure dressing 104. The seal layer 222 may also be used to secure the interface layer 220 at the tissue site 108. If the cover 244 is applied to the tissue surrounding the tissue site 108 with wrinkles in the cover 244, then the seal layer 222 assists in maintaining in the wrinkled areas of the cover 244.
The seal layer 222 may be any size and thickness capable of providing a seal around the tissue site 108. In the example of
While the seal layer 222 illustrated in
The seal layer 222 may be made from any material that is capable of sealing around the treated portion of the tissue site 108. In one illustrative embodiment, the seal layer 222 may include or be made from a hydrogel. The seal layer 222 may also include either or both of a hydrocolloid or silicon.
Although the seal layer 222 is shown as being disposed adjacent to the interface layer 220, the seal layer 222 may be positioned adjacent or between any of the layers in the reduced pressure dressing 104. Additional details regarding the positioning of the seal layer 222 are discussed in more detail below with reference to
The reduced pressure dressing 104 also includes a first manifold layer 224 for distributing the reduced pressure to and withdrawing liquid, such as exudate, from the interface layer 220. When the seal layer 222 is positioned adjacent the interface layer 220, liquid may be withdrawn from the tissue site 108 through the aperture 231. As a reduced pressure is applied to the reduced pressure dressing 104, the liquid is wicked from the tissue site 108 by the interface layer 220 and drawn through the aperture 231 of the seal layer 222 by the first manifold layer 224.
In one embodiment, a length, L3, and a width, W3, of the aperture 231 is less than the length, L1, and the width, W1, of the interface layer 220. However, in other embodiments, particularly in those embodiments in which one or more other layers are disposed between the seal layer 222 and the interface layer 220, the length, L3, and the width, W3, of the aperture 231 may be equal to or larger than the length, L1, and the width, W1, of the interface layer 220. While the aperture 231 illustrated in
The first manifold layer 224 may have any size, shape, or thickness. For example, the size and shape of the first manifold layer 224 may be customized to provide differing levels of utilization of the absorbent layer 228. The size and shape of the first manifold layer 224 may also be customized based on the size and shape of other components in the reduced pressure dressing 104, such as the size and shape of the interface layer 220, the seal layer 222, the aperture 231, the absorbent layer 228, or other layers in the reduced pressure dressing 104.
The first manifold layer 224 is a biocompatible, porous material that is capable of distributing reduced pressure to the tissue site 108. The first manifold layer 224 may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. The first manifold layer 224 includes a plurality of flow channels or pathways to facilitate distribution of reduced pressure or fluids to or from the tissue site 108. In one embodiment, the first manifold layer 224 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam such as GranuFoam® dressing. If an open-cell foam is used, the porosity may be about 400 to 600 microns or any other porosity capable of adequately manifolding reduced pressure. The flow channels allow fluid communication throughout the portion of first manifold layer 224 having open cells. The cells and flow channels may be uniform in shape and size, or may include patterned or random variations in shape and size. Variations in the shape and size of the cells of the first manifold layer 224 result in variations in the flow channels, and such characteristics may be used to alter the flow characteristics of fluid through first manifold layer 224. The first manifold layer 224 may be either hydrophobic or hydrophilic. In one embodiment, the first manifold layer 224 may be made from the same material as the interface layer 220.
In one embodiment, the first manifold layer 224 may be made from a material that expands upon contact with a liquid, such as exudate from the tissue site 108, such that the first manifold layer 224 will fill a wound site or otherwise contact the tissue site 108. In this embodiment, the first manifold layer 224 may enable the interface layer 220 to be removed, thereby simplifying the construction and reducing the thickness or profile of the reduced pressure dressing 104.
The absorbent layer 228 of the reduced pressure dressing 104 is disposed adjacent the first manifold layer 224 for receiving and absorbing the liquids distributed by the first manifold layer 224. The first manifold layer 224 facilitates the migration of liquid from the tissue site 108 radially outward toward the edges of the first manifold layer 224, as indicated generally by the multi-directional arrows 239 so that the liquid is distributed more uniformly across the absorbent layer 228. The absorbent layer 228 will retain more liquid if the liquid is more uniformly distributed across the surface of the absorbent layer 228.
As used herein, a “surface area” of a layer refers to an area measurement of the layer as may be determined in a plane that is positioned adjacent to or in contact with other layers. In the example illustrated in
A surface area (defined as L3×W3) of the aperture 231 in
The absorbent layer 228 is adapted to absorb liquid, such as exudate, from the tissue site 108 via the interface layer 220 and the first manifold layer 224 through the aperture 231 of the seal layer 222. The absorbent layer 228 is also adapted to manifold and transfer reduced pressure through those layers to the tissue site 108. The absorbent layer 228 may be made from any material capable of absorbing liquid, such as exudate from the tissue site 108. In one embodiment, the absorbent layer 228 may be made from a super absorbent fiber. The super absorbent fibers may hold onto or bond to the liquid in conjunction with a physical or chemical change to the fibers. In one non-limiting example, the super absorbent fiber may include the Super Absorbent Fiber (SAF) material from Technical Absorbents®, Ltd. The absorbent layer 228 may be a sheet or mat of fibrous material in which the fibers absorb liquid from the tissue site 108. The structure of the absorbent layer 228 that contains the fibers may be either woven or non-woven. The fibers in the absorbent layer 228 may gel upon contact with the liquid, thereby trapping the liquid. Spaces or voids between the fibers may allow a reduced pressure that is applied to the reduced pressure dressing 104 to be transferred within and through the absorbent layer 228. In one embodiment, the fiber density of fibers in the absorbent layer 228 may be approximately 1.4 grams per millimeter.
The absorbent layer 228 may have any size, shape, or thickness. If additional liquid storage capacity is desired for the reduced pressure dressing 104, then a larger or thicker absorbent layer 228 may be used. In another example, the size and thickness of the absorbent layer 228 may be reduced for space-saving, convenience, compactness, or cost considerations.
The reduced pressure dressing 104 may also include a diverter layer 232 disposed adjacent to the absorbent layer 228, a second manifold layer 236 disposed adjacent the diverter layer 232, and a liquid-air separator 240 disposed adjacent the second manifold layer 236. The diverter layer 232 includes a plurality of holes 247 though which reduced pressure from the reduced pressure source 110 (see
The diverter layer 232 may be made from any material that enhances the reduced pressure transmission and storage capabilities of an adjacent absorbent layer. For example, the diverter layer 247 may be made from a material that is substantially impermeable to liquid and gas. Alternatively, the material from which the diverter layer 232 is made may instead have a predetermined moisture vapor transfer rate that is consistent with gas permeability. In either example, the diverter layer 232 may still include a pattern of holes for transmitting a greater volume of liquid or gas than that permitted by the gas-permeable material of which the diverter layer 232 is constructed. It should be noted, however, that permeability of the diverter layer 232 to gas but not liquid may result in increased transmission of reduced pressure through the dressing while still directing liquid flow around or near the perimeter of the diverter layer 232.
In the embodiment illustrated in
The fuller utilization of the absorbent layer 228 allows for the reduced pressure dressing 104 to be used for a longer period of time without having to dispose the reduced pressure dressing 104. The need to distribute gas and liquid toward the edges of the absorbent layer 228 may be even greater in the presence of reduced pressure due to the speed at which liquid may flow away from the tissue site 108 through the reduced pressure dressing 104.
The diverter layer 232 has primarily been described as assisting in diverting reduced pressure or fluid flow to a perimeter region of the absorbent layer 228. Alternatively, the diverter layer 232 could instead be configured to assist in diverting reduced pressure to any particular region, i.e. a target region, of the absorbent layer 228 to encourage liquid absorption within the target region. For example, if a tissue site and a dressing were of a configuration that naturally resulted in liquid collection in a perimeter region of a particular absorbent layer, then a diverter layer could be configured to encourage liquid collection within the center region of the absorbent layer. In this particular example, the center region would be the target region.
Referring still to
In one embodiment of the reduced pressure dressing 104, the liquid-air separator 240 may be a hydrophobic filter that inhibits or prevents passage of liquids through the liquid-air separator 240. Alternatively, the liquid-air separator 240 may be a gravity-based barrier system, or a device that includes a hydrophilic surface to encourage condensation or other separation of liquid from a fluid stream when the fluid stream passes over the surface. Other examples of liquid-air separators 240 may include sintered metals, sintered nylons, or any other material or device that is capable of separating liquid from a fluid stream, or that is otherwise capable of inhibiting or preventing the passage of liquid while allowing the passage of gases.
By restraining or preventing the flow of liquid, the liquid-air separator 240 prevents liquid from reaching the tubing adapter 116 or conduit 112 (see
The liquid-air separator 240 may prevent the passage of reduced pressure to the tissue site 108 when the liquid-air separator 240 becomes saturated, clogged, blocked, and/or wetted with liquid from the tissue site 108. The liquid-air separator 240 may also prevent the passage of reduced pressure to the tissue site 108 when a layer that abuts the liquid-air separator 240 becomes saturated with liquid. For example, if the absorbent layer 228 abutted the liquid-air separator 240 in a particular embodiment, the saturation of the absorbent layer 228 with liquid may cause the liquid-air separator 240 to prevent the passage of reduced pressure. The presence of the diverter layer 232 between the liquid-air separator 240 and the absorbent layer 228 prolongs the period of time before the liquid-air separator 240 blocks the passage of reduced pressure.
The liquid-air separator 240 may have any size, shape, or thickness. In one example, the liquid-air separator 240 may be smaller than other layers in the reduced pressure dressing 104 due to cost considerations. The liquid-air separator 240 may also be wider than the tubing adapter 116 and an aperture 260 in the cover 244 so that liquid from the tissue site 108 cannot reach the tubing adapter 116 or the aperture 260.
The cover 244 of the reduced pressure dressing 104 covers at least a portion of the reduced pressure dressing 104. In one embodiment, the cover 244 may fully cover the multiple layers of the reduced pressure dressing 104. In this embodiment, the cover 244 may secure or assist in securing the reduced pressure dressing 104 to the tissue site 108 and in maintaining a seal around the tissue site 108. In this respect, both the cover 244 and the seal layer 222 may work together to create a seal around the tissue site 108. The cover 244 may also provide a protective barrier for the reduced pressure dressing 104 and the tissue site 108.
In the embodiment illustrated in
In one embodiment, the cover 244 may be an adhesive drape. The adhesion of the cover 244 may be due to the nature of the material with which the cover 244 is made, or may be due to an adhesive layer disposed on a surface of the cover 244. Any portion of the cover 244 may include adhesive. For example, an entire tissue facing side of the cover 244 may include adhesive. When provided with adhesive, the cover 244 may adhere to at least a portion of the tubing adapter 116, the tissue surrounding the tissue site 108, or any layer or component of the reduced pressure dressing 104. In another embodiment, only the peripheral portions of the tissue facing side of the cover 244 may include adhesive. In this particular case, the adhesive-covered peripheral portions may be adapted to adhere to any of the diverter layer 232, the seal layer 222, and the tissue surrounding the tissue site 108.
In still another embodiment, the cover 244 may be designed such that the cover 244 will not adhere to wet surfaces, but will adhere to dry surfaces. Thus, when applying the cover 244, the cover 244 will not stick to moistened gloves or hands, thereby permitting easier handling of the cover 244 until the cover 244 is placed on a dry tissue site, such as a dry periwound area. The cover 244 may be any size, shape, or thickness. In one example, the cover 244 may be larger than any layer or components of the reduced pressure dressing 104. In another example, the size of the seal layer 222 may be larger than the size of the cover 244.
Reduced pressure may be applied to the plurality of layers of the reduced pressure dressing 104 via the aperture 260 in the cover 244. In the example of
The tubing adapter 116 provides an interface between conduit 112 and the reduced pressure dressing 104. In particular, the tubing adapter 116 fluidly communicates with the conduit 112 such that the conduit 112 transfers reduced pressure to the reduced pressure dressing 104 and the tissue site 108 via the tubing adapter 116.
Referring to
Although not shown in
The reduced pressure dressing 104 may further include an indicator (not shown) to alert a user when the reduced pressure dressing 104 has reached a full liquid storage capacity and needs to be removed from the tissue site 108. In one embodiment, the indicator may be a chemical or other substance that is capable of changing visual appearance or some other characteristic in the presence of moisture. For example, an indicator may be placed in one of the layers between the cover 244 and the absorbent layer 228 such that the indicator undergoes a visible color change when liquid has fully saturated the absorbent layer and is pulled through the absorbent layer into contact with the indicator. In one embodiment, the indicator may be a part of the liquid-air separator 240. The indicator may instead be a part of a separate indicator layer that is positioned anywhere in the dressing to signal the presence of moisture in a particular area. The indicator may cooperate with another layer of the dressing that is transparent to allow a user to view the location at which the indicator is positioned.
Although the cover 244, the liquid-air separator 240, the manifolds 224 and 236, the diverter layer 232, the absorbent layer 228, the seal layer 222, and the interface layer 220 have substantially square shapes in
While the various layers of the reduced pressure dressing 104 have been described as being “adjacent” to other layers, the term “adjacent” may refer to the layers being immediately adjacent, or alternatively that the layers may be positioned with other intervening layers in between. The term “layer” generally refers to portions or regions of the dressing that have different material properties or functions than other portions or regions of the dressing (i.e. other layers). The term “layer” is not meant to be spatially limiting however. The properties and functions associated with a particular layer may be combined with the properties and functions of another layer such that a single layer having multiple and different properties and functions is created. More specifically, for example, two or more layers may be physically or chemically bonded or combined to create a single layer without affecting the original material properties or functions of the original components. Conversely, a particular layer of the dressings described herein may be broken into two or more layers that each have similar properties or functions.
Referring more specifically to
The seal layer 222 may be disposed anywhere between the cover 244 and interface layer 220, including between the absorbent layer 228 and interface layer 220. In the example of
The seal layer 222 also includes overhanging portions 329, which extend past the edges of the interface layer 220. The overhanging portions 329 may be adapted to adhere or otherwise contact the tissue site 108 such that a seal is created at a portion of the tissue site 108. For example, the overhanging portion 329 may adhere or otherwise contact a periwound area surrounding a wound site such that a seal is created at the wound site.
The first manifold layer 224 may also be disposed anywhere in the reduced pressure dressing 104. In one example, the first manifold layer 224 is disposed between the interface layer 220 and the absorbent layer 228. In the non-limiting example of
In the embodiment illustrated in
The second manifold layer 236 may be disposed between the absorbent layer 228 and the cover 244, or between the diverter layer 232 and the cover 244. In
The liquid-air separator 240 may be disposed between the absorbent layer 228 and the cover 244, or between the second manifold layer 236 and the cover 244. In
A tissue facing side 351 of the tubing adapter 116 abuts the liquid-air separator 240. Also, a portion of the tubing adapter 116 is shown to protrude from an aperture in the cover 244. The flange 266 of the tubing adapter 116 is sandwiched between the cover 244 and the liquid-air separator 240 such that the cover 244 secures the tubing adapter 116 to at least one of the plurality of layers, such as the liquid-air separator 240. As illustrated in
The cover 244 may cover all or a part of the reduced pressure dressing 104. For example, the ends of the cover 244 may terminate at a location on the overhanging portions 329 of the seal layer 222. As indicated by the broken lines 380, the cover 244 may also terminate at a location on the tissue site 108.
Referring to
Referring to
In some reduced pressure applications, the tissue may produce more exudate at an area away from the center of the dressing. In these cases, a greater amount of liquid may pass through a portion of the holes 547 that are positioned over the main point of exudation. In the example of
Referring to
Referring to
While the diverter layers of
Referring to
The reduced pressure dressing 1000 also includes a second absorbent layer 1040 disposed adjacent the diverter layer 232 on a side opposite the first absorbent layer 228, and a second HME layer 1041 disposed adjacent the opposite side of the second absorbent layer 1040. The second HME layer 1041 may be an open-celled and/or hydrophilic foam. In one example, the HME layer 1041 is made of the same material as the HME foam 1015. Liquid from the tissue site 108 (not shown) is absorbed and drawn into the HME foam 1015 and transferred to the absorbent layer 228. The liquid is absorbed by the absorbent layer 228, and is pulled through the holes 247 of the diverter layer 232, thereby spreading the liquid and leading to higher utilization of the absorbent layer 228. In the non-limiting example in which a hydrogel diverter layer, such as diverter layer 545 in
Referring to
The peripheral portion 1115 may be made from any material, including an elastic or a non-elastic material. In one example, the peripheral portion 1115 includes an aperture. A tissue facing side 1122 of the peripheral portion 1115 may include an adhesive so that the drape 1125 may be used to cover and secure one or more layers, such as the layers of reduced pressure dressing 104. In another embodiment, both the elastic portion 1110 and the peripheral portion 1115 may be made from the same material and be continuous with one another so that no bond is needed between the elastic portion 1115 and the peripheral portion 1115 at the bonding area 1120.
As illustrated in
As an alternative to a drape having an elastic portion, the drape 1125 may instead be made from an inelastic material that is capable of plastically deforming into an expanded position as fluid is collected in a dressing. The drape 1125 may instead include a combination of elastic and inelastic materials, and expansion may be based on both elastic and plastic deformation of the materials.
Referring to
The drapes 1125 and 1325 of
Referring to
The kiss-cut perforations 1405 and 1505 provide a weakened path along which the interface layer may be torn. When a portion of the interface layers 1400 and 1500 is used in a dressing, the interface layer may still have some perforations remaining. However, despite having these perforations, the interface layer is still able to maintain a desirable shape and effectively perform the functions of the interface layer described herein.
Referring to
Referring to
The dressing 1700 includes second manifold layer 236 above the absorbent layer 1740, and liquid-air separator 240 above the second manifold layer 236. The dressing 1700 also includes a seal layer 1724 (similar to the seal layer 222 of
In one embodiment, the components of the dressing 1700 that are adapted to contact a tissue site are the tissue interface layer 1715, the seal layer 1724, and the cover 244. However, the components of the dressing 1700 may be sized such that any of the components may come into contact with the tissue site.
In another illustrative embodiment, a method is provided for collecting fluid in a dressing positioned at a tissue site. The method includes applying a reduced pressure to the tissue site through the dressing, absorbing liquid from the tissue site, and storing the liquid in the dressing. The method further includes preventing the liquid from exiting the dressing. In one embodiment, the step of absorbing liquid from the tissue site is accomplished with an absorbent layer similar to the absorbent layers described herein. The method may further comprise diverting reduced pressure to a target region of the absorbent layer to increase an absorption efficiency associated with the absorbent layer. Diversion of the reduced pressure to the target region may also increase an amount of time that the absorbent layer is able to distribute reduced pressure.
The illustrative embodiments of reduced pressure dressings described herein may contain a diverter layer to ensure that even pressure distribution is maintained as an absorbent layer absorbs fluid. The diverter layer also promotes the efficient use of the absorbent material in the dressing. The illustrative embodiments may also contain a porous hydrophobic filter that prevents the dressing from allowing liquid, such as exudate, from entering a tubing and helping to ensure pressure distribution. The construction of the dressing and the sequence of layers in the illustrative embodiments help to ensure the optimal absorbency of the dressing combined with the communication of reduced pressure to the tissue site.
Current wound dressings are designed to absorb liquid to maintain a moist wound environment while minimizing the risk of maceration, but are unsuited to adequately manifold reduced pressure. Current dressings that are not currently used with reduced pressure will not normally transmit pressure to a tissue site. These current dressings are designed only to absorb fluid and are routinely changed. The dressings described in the illustrative embodiments are adapted to provide therapy and more absorbent capacity both with and without reduced pressure, and may be applied to a large variety of wounds, including low-severity wounds and low-exudating wounds. The dressings described in the illustrative embodiments will allow reduced pressure tissue therapy without impacting the dressings' absorbency.
Without the diversion provided by components such as the diverter layer, liquid may be absorbed by the absorbent layer and concentrated into a restricted area around the point of exudation. This may lead to large amounts of the absorbent layer being unused. For example, when a reduced pressure source of 125 mmHg is connected to a reduced pressure dressing, the absorbent material may release some of the absorbed liquid, which will bypass the rest of the absorbent area and be drawn directly into the tube that connects the reduced pressure source to the dressing. At this point, the dressing may cease to absorb any more liquid, and as the liquid enters the tube, the dressing's ability to transmit reduced pressure to the tissue site is impaired. Furthermore, this may occur when only a fraction of the target fluid quantity has been absorbed. However, by using a diverter layer and other layers described herein, the efficiency of the absorbent layers may be increased so that the reduced pressure dressing is capable of absorbing more liquid and manifolding reduced pressure for a longer period of time.
The components of the reduced pressure dressings described herein are illustrated in a non-limiting spatial configuration that may be altered depending on the implementation. Although the figures show components of the reduced pressure dressings in a particular order, the components may have any order depending on the implementation. Similarly, the inclusion or exclusion of any particular component may vary depending on the particular application.
Dressing with Integrated Pump
The reduced pressure dressings and components in
Referring to
Referring to
The multiple layers of reduced pressure dressing 1804 are similar in shape, size, positioning, and function to the layers of any of the other reduced pressure dressings described herein. In addition to the layers of dressing 1804 listed above, the reduced pressure dressing 1804 includes a pump 1810 that may be integrated into the dressing between the liquid-air separator 1940 and the cover 1944. The pump 1810 may be a micropump that is small and light enough such that the integrated reduced pressure dressing 1804 is able to be maintained on the tissue site 1808. Furthermore, the size and weight of the pump 1810 should be such that the integrated reduced pressure dressing 1804 does not pull or otherwise adversely affect the tissue site 1808. In one embodiment, the pump 1810 may be a disk pump having a piezoelectric actuator similar to that described in International Patent Application No. PCT/GB2006/001487, published as WO 2006/111775, which is hereby incorporated by reference. In an alternative embodiment, the pump 1810 may be a peristaltic pump that is used for pumping a variety of fluids. It should be understood that alternative pump technologies may be utilized and that rotary, linear, or other configurations of pumps may be utilized.
The pump 1810 may be used to create enough reduced pressure to be “therapeutic” for wound therapy. In one embodiment, the pump 1810 has sufficient flow, vacuum, and operation life characteristics to enable continuous application of reduced pressure treatment. The flow may range between about 5-1000 ml/min, the vacuum may range between about 50-200 mmHg, and continuous operating life may last greater than 20 hours. It should be understood that alternative ranges may be utilized depending on the configuration of the integrated reduced pressure dressing 1804, size of wound, type of wound, or otherwise. In one embodiment, multiple pumps may be positioned in a single dressing to deliver increased flow rates or vacuum levels as required. Alternatively, a selection of pumps having different operational capabilities and specifications may be kept on hand by a user or medical practitioner to allow optimization of a pump and dressing combination for a particular tissue site.
The pump 1810 is disposed within the dressing to avoid conduits and external canisters for collection of wound exudate. The pump 1810 may include a valve 1950 or outlet port to release air or exhaust out of the reduced pressure dressing 1804. If valve 1950 is used, the valve 1950 may be in fluid communication with, or may be positioned within, an aperture 1960 of the cover 1944. Alternatively, the cover 1944 may be sealed around an outlet port of the pump 1810 such that gas from the pump 1810 is able to exhaust directly through the aperture 1960. In the embodiment illustrated in
When a piezoelectric-driven pump is used in a dressing, the piezoelectric actuator associated with the pump may be driven at different frequencies to act as a buzzer or vibrating alert system. The alert system may be used to alert a user to an alarm condition such as the presence of a leak in the dressing, a change in reduced pressure as measured by a sensor, an indication that the dressing has absorbed a maximum capacity of liquid as may be indicated by an indicator, or an indication that one or more layer are no longer manifolding reduced pressure efficiently.
Control electronics 2024 may be utilized to control operation of the pump 1810. The control electronics 2024 may be analog and/or digital and be configured with a regulator (not shown) to regulate speed or duty cycle at which the pump 1810 operates. Furthermore, the control electronics 2024 may be configured with a controller (not shown) that receives sense signals from sensors or switches (not shown). The sensors may be disposed throughout the integrated reduced pressure dressing 1804 to sense parameters, such as pressure, temperature, moisture, chemistry, odor, or any other parameter that may be utilized in managing and controlling the pump 1810. In one embodiment, the control electronics 2024 include a computer processor. Alternatively, the control electronics 2024 may include a programmable gate array. Still yet, the control electronics 2024 may be formed of analog electronic components. It should be understood that the control electronics 2024 may include any form of digital and/or analog components to perform functionality as described herein.
As understood in the art, there are four basic parameters that are of concern when performing reduced pressure wound treatment, including (i) low pressure, (ii) excessive leak, (iii) level of absorbent layer, and (iv) battery state. Accordingly, the control electronics 2024 may include electronics that may be utilized to monitor each of the four basic parameters and generate an alarm signal (e.g., high-pitched beep, vibration, or light) using a speaker (not shown), vibrator (not shown), or illumination device (not shown), such as a light emitting diode (LED), to notify a medical professional, patient, or family member that a parameter is outside of a safe range. For example, if a pressure at the wound site is below a therapeutic level, a continuous tone may be generated. As another example, if the absorbent layer 1928 is saturated, then continuous beeps may be generated. Still yet, if the battery drops below a certain voltage level, then a different frequency may be generated and/or LED may be turned on. A variety of different alarm signals may be established to notify a medical professional to take a particular action.
A battery 2026 may be utilized to provide electric power to the pump 1810 and control electronics 2024. The battery 2026 may have any size and shape configuration and be of any material, such as polymer, to accommodate weight and size of the integrated reduced pressure dressing 1804, as previously described. In one embodiment, the battery 2026 may be rechargeable. In another embodiment, the battery 2026 may be disposed within or outside of the integrated reduced pressure dressing 1804 and be positioned in such a manner as to allow for easy replacement or recharging. In one embodiment, the battery 2026 may be configured with a voltage level sensor (not shown) that is monitored by the control electronics 2024 for determination of a low power level. In one embodiment, the battery 2026 may be directly connected with the pump 1810. Alternatively, the battery 2026 may be connected to the control electronics 2024 that use power from the battery 2026 to drive the pump 1810. The control electronics 2024 may provide continuous power, modulated power, such as a pulsewidth modulated (PWM) signal, to drive the pump 1810.
The seal layer 1922 may be adhered to or otherwise connected to the cover layer 1944 that is used to drape or otherwise cover the integrated reduced pressure dressing 1804. The seal layer 1922 may include an aggressive or medical grade adhesive material that is strong enough to form a vacuum seal with skin around a wound of a patient. The seal layer 1922 may be a band that has an opening 2032 that is slightly larger than the geometric parameters as the hydrophobic filter 2020 or other layer so that the cover layer 2030 may contact skin around the wound site of a patient. The cover layer 2030 may be impermeable to fluids, such as air and liquids. In one embodiment, the cover layer 2030 includes a valve 2034 to enable exhaust from the pump 1810 to be discharged from the integrated reduced pressure dressing 1804. The valve 2034 may be a one-way valve to minimize fluids from entering into the integrated reduced pressure dressing 1804 via the cover layer 2030.
In another embodiment, the seal layer 1922 may be adhered to the diverter layer 1932 and the diverter layer 1932 adhered to the cover 1944 to create an upper dressing portion and a lower dressing portion. The upper dressing portion may include the cover 1944, the pump 1810 and related components, the liquid-air separator 1940, the second manifold layer 1936, and the diverter layer 1932. The lower dressing portion may include the absorbent layer 1928, the first manifold layer 1924, the seal layer 1922, and the interface layer 1920. In one embodiment, the reduced pressure dressing may be configured to allow replacement of the lower dressing portion once the dressing has absorbed a maximum capacity of fluid. The upper dressing portion may be reused after the lower dressing portion is replaced. This allows multiple use of the pump 1810, while disposable portions of the dressing may be replaced. In another embodiment, the pump 1810, control electronics 2024, and battery 2026 may be removed from the dressing for reuse and the remaining layers of the dressing replaced. In still another embodiment, the absorbent layer 1928 only may be replaced. In yet another embodiment, the absorbent layer 1928 and the interface layer 1920 only may be replaced.
A charcoal filter 2036 may be utilized in the integrated reduced pressure dressing 1804 to reduce odors created by the wound site and dispersed from the integrated reduced pressure dressing 1804. The charcoal filter 2036 may be disposed above a valve or other output vent from the pump 1810 to filter exhaust from the pump 1810 prior to being released from the integrated reduced pressure dressing 1804. It should be understood that the charcoal filter 2036 may be alternatively configured and disposed above or below the pump 1810. Still yet, rather than using a charcoal filter, charcoal may be integrated into any or all of the different layers utilized in the integrated reduced pressure dressing 1804.
In another illustrative embodiment, a method for collecting liquid in a dressing positioned at a tissue site includes generating a reduced pressure using a pump positioned within the dressing. A liquid is absorbed from the tissue site and is stored in the dressing. The liquid is prevented from entering the pump. The method may further include maintaining the reduced pressure within the dressing and exhausting gas from the pump outside the dressing.
It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
This application is a divisional of U.S. application Ser. No. 13/709,255, filed Dec. 10, 2012, which is a continuation of U.S. application Ser. No. 12/398,904, filed Mar. 5, 2009, which claims the benefit of U.S. Provisional Application No. 61/034,013, filed Mar. 5, 2008, and U.S. Provisional Application No. 61/049,028, filed Apr. 30, 2008. Each of the applications referenced above are hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1355846 | Rannells | Oct 1920 | A |
| 1944834 | Bennett | Jan 1934 | A |
| 2547758 | Kelling | Apr 1951 | A |
| 2552664 | Burdine | May 1951 | A |
| 2632443 | Lesher | Mar 1953 | A |
| 2682873 | Evans et al. | Jul 1954 | A |
| 2860081 | Eiken | Nov 1958 | A |
| 2910763 | Lauterbach | Nov 1959 | A |
| 2969057 | Simmons | Jan 1961 | A |
| 3066672 | Crosby, Jr. et al. | Dec 1962 | A |
| 3172808 | Baumann et al. | Mar 1965 | A |
| 3183116 | Schaar | May 1965 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3376868 | Mondiadis | Apr 1968 | A |
| 3520300 | Flower, Jr. | Jul 1970 | A |
| 3568675 | Harvey | Mar 1971 | A |
| 3648692 | Wheeler | Mar 1972 | A |
| 3682180 | McFarlane | Aug 1972 | A |
| 3742952 | Magers et al. | Jul 1973 | A |
| 3774611 | Tussey et al. | Nov 1973 | A |
| 3777016 | Gilbert | Dec 1973 | A |
| 3779243 | Tussey et al. | Dec 1973 | A |
| 3826254 | Mellor | Jul 1974 | A |
| 3852823 | Jones | Dec 1974 | A |
| 3903882 | Augurt | Sep 1975 | A |
| 3967624 | Milnamow | Jul 1976 | A |
| 3983297 | Ono et al. | Sep 1976 | A |
| 4060081 | Yannas et al. | Nov 1977 | A |
| 4080970 | Miller | Mar 1978 | A |
| 4096853 | Weigand | Jun 1978 | A |
| 4139004 | Gonzalez, Jr. | Feb 1979 | A |
| 4141361 | Snyder | Feb 1979 | A |
| 4163822 | Walter | Aug 1979 | A |
| 4165748 | Johnson | Aug 1979 | A |
| 4184510 | Murry et al. | Jan 1980 | A |
| 4233969 | Lock et al. | Nov 1980 | A |
| 4245630 | Lloyd et al. | Jan 1981 | A |
| 4256109 | Nichols | Mar 1981 | A |
| 4261363 | Russo | Apr 1981 | A |
| 4275721 | Olson | Jun 1981 | A |
| 4284079 | Adair | Aug 1981 | A |
| 4297995 | Golub | Nov 1981 | A |
| 4333468 | Geist | Jun 1982 | A |
| 4360015 | Mayer | Nov 1982 | A |
| 4373519 | Errede et al. | Feb 1983 | A |
| 4382441 | Svedman | May 1983 | A |
| 4392853 | Muto | Jul 1983 | A |
| 4392858 | George et al. | Jul 1983 | A |
| 4414970 | Berry | Nov 1983 | A |
| 4419097 | Rowland | Dec 1983 | A |
| 4465485 | Kashmer et al. | Aug 1984 | A |
| 4475909 | Eisenberg | Oct 1984 | A |
| 4480638 | Schmid | Nov 1984 | A |
| 4525166 | Leclerc | Jun 1985 | A |
| 4525374 | Vaillancourt | Jun 1985 | A |
| 4529402 | Weilbacher et al. | Jul 1985 | A |
| 4540412 | Van Overloop | Sep 1985 | A |
| 4543100 | Brodsky | Sep 1985 | A |
| 4548202 | Duncan | Oct 1985 | A |
| 4551139 | Plaas et al. | Nov 1985 | A |
| 4569348 | Hasslinger | Feb 1986 | A |
| 4600146 | Ohno | Jul 1986 | A |
| 4605399 | Weston et al. | Aug 1986 | A |
| 4608041 | Nielsen | Aug 1986 | A |
| 4640688 | Hauser | Feb 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4664652 | Weilbacher | May 1987 | A |
| 4664662 | Webster | May 1987 | A |
| 4710165 | McNeil et al. | Dec 1987 | A |
| 4715857 | Juhasz et al. | Dec 1987 | A |
| 4733659 | Edenbaum et al. | Mar 1988 | A |
| 4743232 | Kruger | May 1988 | A |
| 4753230 | Carus et al. | Jun 1988 | A |
| 4758220 | Sundblom et al. | Jul 1988 | A |
| 4787888 | Fox | Nov 1988 | A |
| 4826494 | Richmond et al. | May 1989 | A |
| 4832008 | Gilman | May 1989 | A |
| 4838883 | Matsuura | Jun 1989 | A |
| 4840187 | Brazier | Jun 1989 | A |
| 4848364 | Bosman | Jul 1989 | A |
| 4863449 | Therriault et al. | Sep 1989 | A |
| 4871611 | LeBel | Oct 1989 | A |
| 4872450 | Austad | Oct 1989 | A |
| 4878901 | Sachse | Nov 1989 | A |
| 4897081 | Poirier et al. | Jan 1990 | A |
| 4906233 | Moriuchi et al. | Mar 1990 | A |
| 4906240 | Reed et al. | Mar 1990 | A |
| 4919654 | Kalt | Apr 1990 | A |
| 4930997 | Bennett | Jun 1990 | A |
| 4941882 | Ward et al. | Jul 1990 | A |
| 4953565 | Tachibana et al. | Sep 1990 | A |
| 4961493 | Kaihatsu | Oct 1990 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 4981474 | Bopp et al. | Jan 1991 | A |
| 4985019 | Michelson | Jan 1991 | A |
| 4995382 | Lang et al. | Feb 1991 | A |
| 4996128 | Aldecoa et al. | Feb 1991 | A |
| 5010883 | Rawlings et al. | Apr 1991 | A |
| 5018515 | Gilman | May 1991 | A |
| 5028597 | Kodama et al. | Jul 1991 | A |
| 5037397 | Kalt et al. | Aug 1991 | A |
| 5086170 | Luheshi et al. | Feb 1992 | A |
| 5092323 | Riedel et al. | Mar 1992 | A |
| 5092858 | Benson et al. | Mar 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112323 | Winkler et al. | May 1992 | A |
| 5134994 | Say | Aug 1992 | A |
| 5149331 | Ferdman et al. | Sep 1992 | A |
| 5151314 | Brown | Sep 1992 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5167613 | Karami et al. | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5180375 | Feibus | Jan 1993 | A |
| 5215522 | Page et al. | Jun 1993 | A |
| 5232453 | Plass et al. | Aug 1993 | A |
| 5246775 | Loscuito | Sep 1993 | A |
| 5261893 | Zamierowski | Nov 1993 | A |
| 5266372 | Arakawa et al. | Nov 1993 | A |
| 5270358 | Asmus | Dec 1993 | A |
| 5278100 | Doan et al. | Jan 1994 | A |
| 5279550 | Habib et al. | Jan 1994 | A |
| 5298015 | Komatsuzaki et al. | Mar 1994 | A |
| 5342329 | Croquevielle | Aug 1994 | A |
| 5342376 | Ruff | Aug 1994 | A |
| 5344415 | DeBusk et al. | Sep 1994 | A |
| 5356386 | Goldberg et al. | Oct 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5384174 | Ward et al. | Jan 1995 | A |
| 5387207 | Dyer et al. | Feb 1995 | A |
| 5419769 | Devlin et al. | May 1995 | A |
| 5423778 | Eriksson et al. | Jun 1995 | A |
| 5429590 | Saito et al. | Jul 1995 | A |
| 5437622 | Carion | Aug 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5445604 | Lang | Aug 1995 | A |
| 5447492 | Cartmell et al. | Sep 1995 | A |
| 5458938 | Nygard et al. | Oct 1995 | A |
| 5501212 | Psaros | Mar 1996 | A |
| 5522808 | Skalla | Jun 1996 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5549585 | Maher et al. | Aug 1996 | A |
| 5556375 | Ewall | Sep 1996 | A |
| 5585178 | Calhoun et al. | Dec 1996 | A |
| 5599292 | Yoon | Feb 1997 | A |
| 5607388 | Ewall | Mar 1997 | A |
| 5611373 | Ashcraft | Mar 1997 | A |
| 5634893 | Rishton | Jun 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5641506 | Talke et al. | Jun 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| 5653224 | Johnson | Aug 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5710233 | Meckel et al. | Jan 1998 | A |
| 5714225 | Hansen et al. | Feb 1998 | A |
| 5736470 | Schneberger et al. | Apr 1998 | A |
| 5776119 | Bilbo et al. | Jul 1998 | A |
| 5807295 | Hutcheon et al. | Sep 1998 | A |
| 5878971 | Minnema | Mar 1999 | A |
| 5902439 | Pike et al. | May 1999 | A |
| 5919476 | Fischer et al. | Jul 1999 | A |
| 5941863 | Guidotti et al. | Aug 1999 | A |
| 5964252 | Simmons et al. | Oct 1999 | A |
| 5981822 | Addison | Nov 1999 | A |
| 5998561 | Jada | Dec 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6086995 | Smith | Jul 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| 6174306 | Fleischmann | Jan 2001 | B1 |
| 6191335 | Robinson | Feb 2001 | B1 |
| 6241747 | Ruff | Jun 2001 | B1 |
| 6262329 | Brunsveld et al. | Jul 2001 | B1 |
| 6287316 | Agarwal et al. | Sep 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6488643 | Tumey et al. | Dec 2002 | B1 |
| 6493568 | Bell et al. | Dec 2002 | B1 |
| 6495229 | Carte et al. | Dec 2002 | B1 |
| 6503855 | Menzies et al. | Jan 2003 | B1 |
| 6548727 | Swenson | Apr 2003 | B1 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6566575 | Stickels et al. | May 2003 | B1 |
| 6566577 | Addison et al. | May 2003 | B1 |
| 6626891 | Ohmstede | Sep 2003 | B2 |
| 6627215 | Dale et al. | Sep 2003 | B1 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6680113 | Lucast et al. | Jan 2004 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6693180 | Lee et al. | Feb 2004 | B2 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6856821 | Johnson | Feb 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7154017 | Sigurjonsson et al. | Dec 2006 | B2 |
| 7402721 | Sigurjonsson et al. | Jul 2008 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7645269 | Zamierowski | Jan 2010 | B2 |
| 8298197 | Eriksson et al. | Oct 2012 | B2 |
| 8529532 | Pinto et al. | Sep 2013 | B2 |
| 8632523 | Eriksson et al. | Jan 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 9192444 | Locke et al. | Nov 2015 | B2 |
| 20010030304 | Kohda et al. | Oct 2001 | A1 |
| 20010051178 | Blatchford et al. | Dec 2001 | A1 |
| 20020009568 | Bries et al. | Jan 2002 | A1 |
| 20020016346 | Brandt et al. | Feb 2002 | A1 |
| 20020065494 | Lockwood et al. | May 2002 | A1 |
| 20020077661 | Saadat | Jun 2002 | A1 |
| 20020115951 | Norstrem et al. | Aug 2002 | A1 |
| 20020119292 | Venkatasanthanam et al. | Aug 2002 | A1 |
| 20020120185 | Johnson | Aug 2002 | A1 |
| 20020130064 | Adams et al. | Sep 2002 | A1 |
| 20020143286 | Tumey | Oct 2002 | A1 |
| 20020150270 | Werner | Oct 2002 | A1 |
| 20020150720 | Howard et al. | Oct 2002 | A1 |
| 20020161346 | Lockwood et al. | Oct 2002 | A1 |
| 20020164346 | Nicolette | Nov 2002 | A1 |
| 20020183702 | Henley et al. | Dec 2002 | A1 |
| 20020198504 | Risk et al. | Dec 2002 | A1 |
| 20030014022 | Lockwood et al. | Jan 2003 | A1 |
| 20030109855 | Solem et al. | Jun 2003 | A1 |
| 20030158577 | Ginn et al. | Aug 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030225347 | Argenta et al. | Dec 2003 | A1 |
| 20030225355 | Butler | Dec 2003 | A1 |
| 20040002676 | Siegwart et al. | Jan 2004 | A1 |
| 20040030304 | Hunt et al. | Feb 2004 | A1 |
| 20040064132 | Boehringer et al. | Apr 2004 | A1 |
| 20040077984 | Worthley | Apr 2004 | A1 |
| 20040099268 | Smith et al. | May 2004 | A1 |
| 20040118401 | Smith et al. | Jun 2004 | A1 |
| 20040127836 | Sigurjonsson et al. | Jul 2004 | A1 |
| 20040127862 | Bubb et al. | Jul 2004 | A1 |
| 20040133143 | Burton et al. | Jul 2004 | A1 |
| 20040186239 | Qin et al. | Sep 2004 | A1 |
| 20040219337 | Langley et al. | Nov 2004 | A1 |
| 20040230179 | Shehada | Nov 2004 | A1 |
| 20050034731 | Rousseau et al. | Feb 2005 | A1 |
| 20050054998 | Poccia et al. | Mar 2005 | A1 |
| 20050059918 | Sigurjonsson et al. | Mar 2005 | A1 |
| 20050065484 | Watson | Mar 2005 | A1 |
| 20050070858 | Lockwood et al. | Mar 2005 | A1 |
| 20050101940 | Radl et al. | May 2005 | A1 |
| 20050113732 | Lawry | May 2005 | A1 |
| 20050124925 | Scherpenborg | Jun 2005 | A1 |
| 20050131327 | Lockwood et al. | Jun 2005 | A1 |
| 20050137539 | Biggie et al. | Jun 2005 | A1 |
| 20050143694 | Schmidt et al. | Jun 2005 | A1 |
| 20050159695 | Cullen et al. | Jul 2005 | A1 |
| 20050161042 | Fudge et al. | Jul 2005 | A1 |
| 20050163978 | Strobech et al. | Jul 2005 | A1 |
| 20050214376 | Faure et al. | Sep 2005 | A1 |
| 20050233072 | Stephan et al. | Oct 2005 | A1 |
| 20050256437 | Silcock et al. | Nov 2005 | A1 |
| 20050261642 | Weston | Nov 2005 | A1 |
| 20050261643 | Bybordi et al. | Nov 2005 | A1 |
| 20050277860 | Jensen | Dec 2005 | A1 |
| 20060079852 | Bubb et al. | Apr 2006 | A1 |
| 20060083776 | Bott et al. | Apr 2006 | A1 |
| 20060154546 | Murphy et al. | Jul 2006 | A1 |
| 20060236979 | Stolarz et al. | Oct 2006 | A1 |
| 20060241542 | Gudnason et al. | Oct 2006 | A1 |
| 20060271020 | Huang et al. | Nov 2006 | A1 |
| 20070027414 | Hoffman et al. | Feb 2007 | A1 |
| 20070078366 | Haggstrom | Apr 2007 | A1 |
| 20070161937 | Aali | Jul 2007 | A1 |
| 20070185426 | Ambrosio et al. | Aug 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070265585 | Joshi et al. | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20080027366 | Da Silva Macedo | Jan 2008 | A1 |
| 20080090085 | Kawate et al. | Apr 2008 | A1 |
| 20080119802 | Riesinger | May 2008 | A1 |
| 20080138591 | Graham et al. | Jun 2008 | A1 |
| 20080149104 | Eifler | Jun 2008 | A1 |
| 20080173389 | Mehta et al. | Jul 2008 | A1 |
| 20080195017 | Robinson et al. | Aug 2008 | A1 |
| 20080225663 | Smith et al. | Sep 2008 | A1 |
| 20080243044 | Hunt et al. | Oct 2008 | A1 |
| 20080269657 | Brenneman et al. | Oct 2008 | A1 |
| 20080271804 | Biggie et al. | Nov 2008 | A1 |
| 20090025724 | Herron, Jr. | Jan 2009 | A1 |
| 20090088719 | Driskell | Apr 2009 | A1 |
| 20090093779 | Riesinger | Apr 2009 | A1 |
| 20090124988 | Coulthard | May 2009 | A1 |
| 20090177172 | Wilkes | Jul 2009 | A1 |
| 20090216204 | Bhavaraju et al. | Aug 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090264807 | Haggstrom et al. | Oct 2009 | A1 |
| 20090292264 | Hudspeth et al. | Nov 2009 | A1 |
| 20090312662 | Colman et al. | Dec 2009 | A1 |
| 20090326488 | Budig et al. | Dec 2009 | A1 |
| 20100063467 | Addison et al. | Mar 2010 | A1 |
| 20100106106 | Heaton et al. | Apr 2010 | A1 |
| 20100106118 | Heaton et al. | Apr 2010 | A1 |
| 20100125259 | Olson | May 2010 | A1 |
| 20100159192 | Cotton | Jun 2010 | A1 |
| 20100185163 | Heagle | Jul 2010 | A1 |
| 20100226824 | Ophir et al. | Sep 2010 | A1 |
| 20100262090 | Riesinger | Oct 2010 | A1 |
| 20100267302 | Kantner et al. | Oct 2010 | A1 |
| 20100305490 | Coulthard et al. | Dec 2010 | A1 |
| 20100305524 | Vess et al. | Dec 2010 | A1 |
| 20100324516 | Braga et al. | Dec 2010 | A1 |
| 20110046585 | Weston | Feb 2011 | A1 |
| 20110137271 | Andresen et al. | Jun 2011 | A1 |
| 20110160686 | Ueda et al. | Jun 2011 | A1 |
| 20110171480 | Mori et al. | Jul 2011 | A1 |
| 20110172617 | Riesinger | Jul 2011 | A1 |
| 20110224631 | Simmons et al. | Sep 2011 | A1 |
| 20110229688 | Cotton | Sep 2011 | A1 |
| 20110244010 | Doshi | Oct 2011 | A1 |
| 20110257617 | Franklin | Oct 2011 | A1 |
| 20120016322 | Coulthard et al. | Jan 2012 | A1 |
| 20120040131 | Speer | Feb 2012 | A1 |
| 20120123359 | Reed | May 2012 | A1 |
| 20120143157 | Riesinger | Jun 2012 | A1 |
| 20120258271 | Maughan | Oct 2012 | A1 |
| 20130030394 | Locke et al. | Jan 2013 | A1 |
| 20130066285 | Locke et al. | Mar 2013 | A1 |
| 20130096518 | Hall et al. | Apr 2013 | A1 |
| 20130152945 | Locke et al. | Jun 2013 | A1 |
| 20140039423 | Riesinger | Feb 2014 | A1 |
| 20140039424 | Locke | Feb 2014 | A1 |
| 20140141197 | Hill et al. | May 2014 | A1 |
| 20140155849 | Heaton et al. | Jun 2014 | A1 |
| 20140171851 | Addison | Jun 2014 | A1 |
| 20140309574 | Cotton | Oct 2014 | A1 |
| 20140350494 | Hartwell et al. | Nov 2014 | A1 |
| 20150030848 | Goubard | Jan 2015 | A1 |
| 20150119830 | Luckemeyer et al. | Apr 2015 | A1 |
| 20150190286 | Allen et al. | Jul 2015 | A1 |
| 20160000610 | Riesinger | Jan 2016 | A1 |
| 20160067107 | Cotton | Mar 2016 | A1 |
| 20160144084 | Collinson et al. | May 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 550575 | Mar 1986 | AU |
| 745271 | Mar 2002 | AU |
| 755496 | Dec 2002 | AU |
| 2009200608 | Oct 2009 | AU |
| 2005436 | Jun 1990 | CA |
| 87101823 | Aug 1988 | CN |
| 26 40 413 | Mar 1978 | DE |
| 43 06 478 | Sep 1994 | DE |
| 29 504 378 | Sep 1995 | DE |
| 202004018245 | Jul 2005 | DE |
| 202014100383 | Feb 2015 | DE |
| 097517 | Jan 1984 | EP |
| 0097517 | Jan 1984 | EP |
| 0100148 | Feb 1984 | EP |
| 0117632 | Sep 1984 | EP |
| 0147119 | Jul 1985 | EP |
| 0161865 | Nov 1985 | EP |
| 0251810 | Jan 1988 | EP |
| 0275353 | Jul 1988 | EP |
| 0358302 | Mar 1990 | EP |
| 0538917 | Apr 1993 | EP |
| 0630629 | Dec 1994 | EP |
| 0659390 | Jun 1995 | EP |
| 0633758 | Oct 1996 | EP |
| 1002846 | May 2000 | EP |
| 1018967 | Jul 2000 | EP |
| 2578193 | Apr 2013 | EP |
| 692578 | Jun 1953 | GB |
| 1386800 | Mar 1975 | GB |
| 2 195 255 | Apr 1988 | GB |
| 2 197 789 | Jun 1988 | GB |
| 2 220 357 | Jan 1990 | GB |
| 2 235 877 | Mar 1991 | GB |
| 2 329 127 | Mar 1999 | GB |
| 2 333 965 | Aug 1999 | GB |
| 2377939 | Jan 2003 | GB |
| 2392836 | Mar 2004 | GB |
| 2393655 | Apr 2004 | GB |
| 2425487 | Nov 2006 | GB |
| 2452720 | Mar 2009 | GB |
| 2496310 | May 2013 | GB |
| 1961003393 | Feb 1961 | JP |
| S62139523 | Sep 1987 | JP |
| S62-275456 | Nov 1987 | JP |
| 2007254515 | Oct 2007 | JP |
| 2008080137 | Apr 2008 | JP |
| 4129536 | Aug 2008 | JP |
| 71559 | Apr 2002 | SG |
| 8002182 | Oct 1980 | WO |
| 8704626 | Aug 1987 | WO |
| 8707164 | Dec 1987 | WO |
| 90010424 | Sep 1990 | WO |
| 93009727 | May 1993 | WO |
| 94020041 | Sep 1994 | WO |
| 9605873 | Feb 1996 | WO |
| 9622753 | Aug 1996 | WO |
| 9718007 | May 1997 | WO |
| 9913793 | Mar 1999 | WO |
| 9965542 | Dec 1999 | WO |
| 01019306 | Mar 2001 | WO |
| 0136188 | May 2001 | WO |
| 0160296 | Aug 2001 | WO |
| 0168021 | Sep 2001 | WO |
| 0185248 | Nov 2001 | WO |
| 0185248 | Nov 2001 | WO |
| 01085248 | Nov 2001 | WO |
| 0243743 | Jun 2002 | WO |
| 02062403 | Aug 2002 | WO |
| 03018098 | Mar 2003 | WO |
| 03045294 | Jun 2003 | WO |
| 03045492 | Jun 2003 | WO |
| 03053484 | Jul 2003 | WO |
| 2004024197 | Mar 2004 | WO |
| 2004037334 | May 2004 | WO |
| 2004112852 | Dec 2004 | WO |
| 2005002483 | Jan 2005 | WO |
| 2005062896 | Jul 2005 | WO |
| 2005105176 | Nov 2005 | WO |
| 2005123170 | Dec 2005 | WO |
| 2007022097 | Feb 2007 | WO |
| 2007030601 | Mar 2007 | WO |
| 2007070269 | Jun 2007 | WO |
| 2007085396 | Aug 2007 | WO |
| 2007087811 | Aug 2007 | WO |
| 2007113597 | Oct 2007 | WO |
| 2007133618 | Nov 2007 | WO |
| 2008026117 | Mar 2008 | WO |
| 2008041926 | Apr 2008 | WO |
| 2008048527 | Apr 2008 | WO |
| 2008054312 | May 2008 | WO |
| 2008082444 | Jul 2008 | WO |
| 2008100440 | Aug 2008 | WO |
| 2008104609 | Sep 2008 | WO |
| 2008131895 | Nov 2008 | WO |
| 2009002260 | Dec 2008 | WO |
| 2008149107 | Dec 2008 | WO |
| 2009066105 | May 2009 | WO |
| 2009066106 | May 2009 | WO |
| 2009081134 | Jul 2009 | WO |
| 2009089016 | Jul 2009 | WO |
| 2009124100 | Oct 2009 | WO |
| 2009126103 | Oct 2009 | WO |
| 2010016791 | Feb 2010 | WO |
| 2010032728 | Mar 2010 | WO |
| 2010056977 | May 2010 | WO |
| 2010129299 | Nov 2010 | WO |
| 2011008497 | Jan 2011 | WO |
| 2011049562 | Apr 2011 | WO |
| 2011043786 | Apr 2011 | WO |
| 2011115908 | Sep 2011 | WO |
| 2011121127 | Oct 2011 | WO |
| 2011130570 | Oct 2011 | WO |
| 2011162862 | Dec 2011 | WO |
| 2012112204 | Aug 2012 | WO |
| 2012104584 | Aug 2012 | WO |
| 2012140378 | Oct 2012 | WO |
| 2012143665 | Oct 2012 | WO |
| 2013009239 | Jan 2013 | WO |
| 2013090810 | Jun 2013 | WO |
| 2014039557 | Mar 2014 | WO |
| 2014078518 | May 2014 | WO |
| 2014113253 | Jul 2014 | WO |
| 2014140608 | Sep 2014 | WO |
| 2014143488 | Sep 2014 | WO |
| 2015065615 | May 2015 | WO |
| 2015130471 | Sep 2015 | WO |
| 2017048866 | Mar 2017 | WO |
| Entry |
|---|
| Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery. |
| Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
| James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
| John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 198, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
| S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
| George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
| Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
| International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
| PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
| PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
| PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
| PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
| Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
| Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
| Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
| Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
| Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
| Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
| Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
| Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
| Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
| Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
| Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
| Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
| Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
| Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
| N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (certified translation). |
| K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
| G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
| F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
| A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
| M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
| D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
| M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
| C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ”Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
| Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
| V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
| V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
| V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
| V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
| Response dated Oct. 21, 2011 for U.S. Appl. No. 12/398,891. |
| Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,891. |
| Restriction Requirement dated Jun. 13, 2011 for U.S. Appl. No. 12/398,891. |
| Response dated Jun. 24, 2011 for U.S. Appl. No. 12/398,891. |
| Non-Final Office Action dated Jul. 21, 2011 for U.S. Appl. No. 12/398,891. |
| International Search Report and Written Opinion dated May 31, 2010 for PCT Application No. PCT/US2009/064364. |
| Partial International Search Report dated Jul. 31, 2009 for PCT International Application No. PCT/US2009/036217. |
| International Search Report and Written Opinion dated Oct. 19, 2010; PCT International Application No. PCT/US2009/036217. |
| International Search Report and Written Opinion dated Jan. 5, 2010; PCT International Application No. PCT/US2009/057130. |
| International Search Report and Written Opinion dated Feb. 24, 2010; PCT International Application No. PCT/US2009/057182. |
| NPD 1000 Negative Pressure Would Therapy System, Kalypto Medical, pp. 1-4. |
| Partial International Search Report dated Jul. 31, 2009; PCT Internationl Application No. PCT/US2009/036222. |
| Non-Final Rejection for U.S. Appl. No. 12/398,904 dated Mar. 14, 2012. |
| Response to Non-Final Rejection for U.S. Appl. No. 12/398,904, filed Jun. 4, 2012. |
| Response dated Oct. 20, 2011 for U.S. Appl. No. 12/398,904. |
| Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,904. |
| International Search Report and Written Opinion for PCT/GB2008/003075 dated Mar. 11, 2010. |
| International Search Report and Written Opinion for PCT/GB2008/004216 dated Jul. 2, 2009. |
| International Search Report and Written Opinion for PCT/GB2012/000099 dated May 2, 2012. |
| EP Examination Report dated May 22, 2014 for EP. |
| International Search Report and Written Opinion for PCT/US2012/069893 dated Apr. 8, 2013. |
| International Search Report and Written Opinion for PCT/US2013/070070 dated Jan. 29, 2014. |
| International Search Report and Written Opinion for PCT/US2014/016320 dated Apr. 15, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056566 dated Dec. 5, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056508 dated Dec. 9, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056524 dated Dec. 11, 2014. |
| International Search Report and Written Opinion for PCT/US2014/056594 dated Dec. 2, 2014. |
| Partial Internationl Search Report dated Jul. 31, 2009; PCT Internationl Application No. PCT/US2009/036222. |
| International Search Report and Written opinion dated Dec. 15, 2009; PCT Internation Application No. PCT/US2009/036222. |
| International Search Report and Written Opinion dated Feb. 24, 2010; PCT/US2009/057182. |
| Non-Final Office Action dated Jul. 20, 2011 for U.S. Appl. No. 12/398,904. |
| V.A. Solovev et al., Guidelines, The Method of Treatment of Immagure External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medican Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
| V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatement of Open Septic Wounds,” in All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Masco, U. S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
| V.A. Solovev, Dissertation Abstract, Treatement and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1998 (“Solovev Abstract”). |
| NDP 1000 Negative Pressure Wound Terapy System, Kalypto Medical, pp. 1-4. |
| Examination report for AU2009221772 dated Apr. 4, 2013. |
| International Search Report and Written Opinion for PCT/US2014/061251 dated May 8, 2015. |
| International Search Report and Written Opinion for PCT/IB2013/060862 dated Jun. 26, 2014. |
| International Search Report and Written Opinion for corresponding PCT application PCT/US2016/051768 dated Dec. 15, 2016. |
| International Search Report and Written Opinion for PCT/US2015/015493 dated May 4, 2015. |
| European Search Report for corresponding Application No. 15194949.2. |
| European Search Report for corresponding EPSN 15157408.4 published on Sep. 30, 2015. |
| International Search Report and Written Opinion for PCT/US2015/034289 dated Aug. 21, 2015. |
| International Search Report and Written Opinion for PCT/US2015/065135 dated Apr. 4, 2016. |
| International Search Report and Written Opinion for PCT/GB2012/050822 dated Aug. 8, 2012. |
| International Search Report and Written Opinion for PCT/US2015/029037 dated Sep. 4, 2015. |
| International Search Report and Written Opinion dated Jun. 1, 2011 for PCT International Application No. PCT/US2011/028344. |
| European Search Report for EP 11714148.1, dated May 2, 2014. |
| European Search Report for corresponding Application No. 15192606.0 dated Feb. 24, 2016. |
| International Search Report and Written Opinion for corresponding PCT/US2014/048081 dated Nov. 14, 2014. |
| International Search Report and Written Opinion for corresponding PCT/US2014/010704 dated Mar. 25, 2014. |
| European Examination Report dated Jun. 29, 2016, corresponding to EP Application No. 16173614.5. |
| M. Waring et al., “Cell attachment to adhesive dressing: qualitative and quantitative analysis”, Wounds, UK, (2008), vol. 4, No. 3, pp. 35-47. |
| R. White, “Evidence for atraumatic soft silicone wound dressing use”. Wound, UK (2005), vol. 3, pp. 104-108, Mepilex Border docs, (2001). |
| European Search Report for corresponding application 17183683.6, dated Sep. 18, 2017. |
| European Search Report for corresponding application 17164033.7, dated Oct. 13, 2017. |
| Extended European Search Report for corresponding application 17191970.7, dated Oct. 26, 2017. |
| European Search Report for corresponding EP Application 171572787 dated Jun. 6, 2017. |
| International Search Report and Written Opinion for corresponding application PCT/US2016/031397. |
| European Search Report for corresponding application 17167872.5, dated Aug. 14, 2017. |
| Office Action for related U.S. Appl. No. 14/965,675, dated Jan. 31, 2018. |
| Office Action for related U.S. Appl. No. 13/982,650, dated Dec. 14, 2017. |
| Australian Office Action for related application 2013344686, dated Nov. 28, 2017. |
| Office Action for related U.S. Appl. No. 14/517,521, dated Dec. 12, 2017. |
| Office Action for related U.S. Appl. No. 14/490,898, dated Jan. 4, 2018. |
| International Search Report and Written Opinion for related appplication PCT/US2017/058209, dated Jan. 10, 2018. |
| Extended European Search Report for related application 17177013.4, dated Mar. 19, 2018. |
| Extended European Search Report for related application 16793298.7, dated Mar. 27, 2018. |
| Number | Date | Country | |
|---|---|---|---|
| 20150258256 A1 | Sep 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61049028 | Apr 2008 | US | |
| 61034013 | Mar 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13709255 | Dec 2012 | US |
| Child | 14703667 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12398904 | Mar 2009 | US |
| Child | 13709255 | US |
